Novartis AG risk profile

25 Normal where most of the sector sits

Measured 1 September 2026 from NVS's filed statements. Recomputed nightly.

25 (Normal), driven by Competitive position at 32, over 5 weighted categories on the MANUFACTURER profile.

What is measured

MechanismReadingBandDirectionDriver
Market expectation20NormalStableOne-year price volatility — 21.9%
Operating pressure19ContainedStableCosts outgrowing revenue — -4.6 percentage points
Cash conversion24NormalStableCash conversion — 1.37x
Leverage and coverage20NormalStableCurrent ratio — 1.12x
Competitive position32NormalStableRevenue-growth gap against peers — +1.0 percentage points
ConcentrationReads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company.

These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.

Healthcare companies with a risk reading

Financials, valuation and price history for Novartis AG